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Abstract 
OBJECTIVE: To determine the prevalence of hearing loss in school-age children who have undergone 
neonatal extracorporeal membrane oxygenation (ECMO) treatment and to identify any effects of 
hearing loss on speech- and language development.  
DESIGN: Prospective longitudinal follow-up study within the framework of a structured post-ECMO 
follow-up program.  
SETTING: Outpatient clinic of a level III university hospital.  
RESULTS: Tone audiometry was performed by standardized protocol in 136 children aged 5 to 12 
years. Hearing loss was considered clinically significant when >20dB. Hearing was normal in 75.7% of 
children. Five children (3.7%) had bilateral sensorineural or combined hearing loss; 3 of them received 
special audiological care (2.2% of total sample). Of the 24 children with congenital diaphragmatic 
hernia, 19 (79.2%) had normal hearing; and only 2 (8.3%) had mild SNHL, unilateral in one of them. 
Follow-up at 24 months of age had shown normal verbal and non-verbal developmental scores. 
Language development and intelligence median (range) scores at 5 years of age were also normal: 
receptive language development 104 (55-133); syntactical development 104 (68-132); and lexical 
development 101 (50-141) for 89 children; intelligence quotient was 104 (68-132) in 106 children. 
Scores did not differ between those with normal hearing, and those with mild hearing loss, or those 
with moderate to severe hearing loss (p=0.800, p=0.639, p=0.876, and p=0.886, for the respective 
developmental tests).   
CONCLUSIONS: We found normal language development and intelligence in a cohort of neonatal 
ECMO survivors. The prevalence of bilateral sensorineural hearing loss was in accordance with that of 
larger series in the United States – which exceeds the prevalence in the normal population.  
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Introduction 
Extracorporeal membrane oxygenation (ECMO) is a supportive intensive-care technique to counteract 
acute reversible cardiorespiratory failure. ECMO provides prolonged cardiopulmonary bypass while 
allowing the lungs to rest using minimal ventilator settings (1). A trial in critically ill neonates conferred 
a survival advantage of ECMO over conventional management – except in cases of congenital 
diaphragmatic hernia (CDH) – without a concomitant increase in severe disability (2).  
Sensorineural hearing loss (SNHL) is one of the disabilities reported in patients who have undergone 
ECMO-treatment (3-5). It was found in 28 of 371 ECMO-survivors (7.5%) from 6 different centers in 
North America (6), Frequencies per center ranged from 3 to 21%; follow-up from 1-10 years. Several 
groups have reported delayed onset of SNHL and therefore advocated ongoing follow-up testing (4, 5, 
7). A number of risk factors for SNHL after neonatal intensive care have been identified: presence of 
CDH (7), prolonged ventilatory support (8, 9) prolonged ECMO (7, 10), sepsis or bacterial meningitis 
(8, 11), prolonged administration of aminoglycosides (7), severe birth asphyxia (9, 11), cerebral 
bleeding or cerebral infarction(11), and clinical seizures prior to ECMO treatment (10). 
Infants with hearing loss (HL) are at risk for delayed speech development and language acquisition, 
impaired academic achievement, and social/ emotional developmental problems (12, 13). Early 
identification of HL and appropriate intervention could prevent or minimize adverse effects on these 
developmental areas (14, 15). To our knowledge only one study – by Desai et al. – explored the 
relationship between hearing loss and language development of ECMO survivors; the relationship 
between neonatal brainstem audiometry results and delayed receptive language ability proved 
uncertain (16). To shed more light on this issue we tested hearing as well as speech- and language 
development in survivors of neonatal ECMO-treatment. The following research questions were 
addressed: 1) What is the prevalence of SNHL after neonatal ECMO treatment?; 2) Does HL affect 
speech- and language development and intelligence? 
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Participants and methods 
Participants 
A cohort of children, now aged between 5 and 12 years, who had received neonatal veno-arterial (VA) 
ECMO support between January 1992 and February 2005, and mainly consisting of children living in 
the referral area of the Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands l. The 
large majority had been treated in this hospital an additional four in the Radboud University Nijmegen 
Medical Center (Nijmegen, the Netherlands), and one in the University Hospitals Leuven (Leuven, 
Belgium). Inclusion criteria and treatment protocols did not differ between these centers. ECMO was 
initiated in case of reversible severe respiratory failure and an estimated mortality risk of higher than 
80% using the entry criteria reported by Stolar et al. (17). 
Entry criteria and exclusion criteria were previously described by our group (18) and did not change 
during the study period. Cerebral ultrasound examinations were performed prior to treatment with 
ECMO, daily during ECMO treatment, and before discharge from our hospital. All subjects of the study 
reported here participate in a prospective post-ECMO follow-up program that provides for regular 
assessments of lung function, growth and developmental parameters until 18 years of age (19). Based 
on the national consensus on neonatal follow-up and the Dutch Ministry of Health’s requirement to 
provide relevant data, the assessment protocol is the standard of care following ECMO treatment. As 
a consequence IRB approval was waived. Parents of all children studied were informed about the 
study and gave written informed consent to evaluate data collected during routine care. 
 
Procedures and study design 
The following clinical characteristics were recorded prospectively: underlying condition, gestational 
age, birth weight, age at onset of ECMO, duration of ECMO support, mean airway pressure (MAP) 
and highest oxygenation index (OI) prior to ECMO, duration of mechanical ventilation before ECMO, 
total duration of mechanical ventilation (including ECMO), duration of oxygen dependency, and 
prevalence of chronic lung disease (CLD). CLD was defined as oxygen dependency at day 28 (20). 
The assessment protocol encompasses hospital consultations at 6, 12, 24 months and 5, 8 and 12 
years of age. Audiometry is routinely performed at 5 years of age. However, because the program 
started in 2001, some children entered not until 8 or 12 years of age. In those cases audiometry was 
performed during their first visit (Figure 1). 
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Hearing assessment 
Audiometry was performed with a Madsen clinical audiometer (OB822; Madson Electronics, Denmark) 
according to the standard procedure used in the Netherlands, including both air conduction and bone 
conduction measurements. Tympanometry was done with an Interacoustics AT 235 h device 
(Interacoustics USA, Eden Prairie, Minnesota), with a 226-Hz probe stimulus. 
 
Assessment of language development and intelligence 
Within the framework of the follow-up program, the Dutch translation of the Bayley Developmental 
Scales (BOS 2-30) had been administered at age 2 years. This standardized instrument assesses 
both verbal and non-verbal development of 2 to 30-month-old children (21). From December 2003, a 
new version of the BOS 2-30 was used: the Bailey Scales of Infant Development – Second Edition – 
Dutch version (BSID-II-NL) (22). The BOS 2-30 and the BSID-II-NL share the same background and 
are substantially related to each other (22). The BSID-II-NL was administered to 8 children. 
At 5 years of age the Reynell Test (receptive language development), the Schlichting Test (syntactical 
and lexical expression), and the short version of the Revised Amsterdam Intelligence Test  were 
administered to assess language development and intelligence, as described previously (19). 
 
Data analysis 
Hearing assessment 
In consultation with the audiologist (A.G.) the audiograms were interpreted as follows. Two frequency 
bands were distinguished: low and high. For the low frequency band the mean HL was calculated at 
500, 1000 and 2000 kHz; for the high frequency band at 2000, 4000 and 8000 kHz. HL severity was 
categorized in terms of clinical consequences. HL <20 dB is “not significant”, thus “normal”; 20-40 dB 
is “mild”; and >40 dB is “moderate to severe”. 
HL was considered symmetrical if it was of the same category in both ears for both frequencies.  
We distinguished between “conductive HL” (>10 dB difference between the bone conduction response 
and the air conduction response) and “SNHL only” (difference ≤10 dB). If both were present HL was 
labelled as: combined. Tympanometry was used to confirm conductive HL. 
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Language development and intelligence 
Language developmental and intelligence scores below 85 (<-1 SD) were categorized as "below 
average"; scores between 85 and 115 (≥ -1 SD and ≤ +1 SD) as "average"; and scores above 115 
(>+1 SD) as "above average". 
 
Statistical methods 
Group comparisons were tested with the Kruskal-Wallis H test. The Mann-Whitney test with Bonferroni 
correction was used for post-hoc analysis. Proportions were compared using the Chi-square test. Data 
on HL and developmental tests for two subgroups – underlying condition CDH or meconium aspiration 
syndrome (MAS) – were analyzed separately. These two subgroups were considered of special 
interest. CDH is associated with abnormal lung development with severe pulmonary hypertension and 
increased prevalence of HL (7, 23, 24); infants with MAS form the largest homogeneous subgroup of 
children treated with ECMO. The other subgroups are small and more heterogeneous with respect to 
underlying disease. Data are presented as mean (SD) or median (range). Statistical significance was 
accepted at a two-sided 5% level for all tests. Statistical analyses were performed using SPSS 17.0 for 
Windows. 
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Results 
Between January 1992 and February 2005 a total of 257 neonates received ECMO in our center and 
5 children from our referral area elsewhere; 76 patients died at neonatal age (29%; CDH n=46 (61%)). 
Of the remaining patients, 34 did not participate in the follow-up program (parents' refusal n=17; other 
reasons n=17), and 13 did not undergo audiometry for different reasons (Figure 1). One of them, a girl 
who had suffered from severe birth asphyxia, had been diagnosed with severe bilateral SNHL at the 
age of 6 months and wore hearing aids. She was evaluated elsewhere. Two other children who had 
been evaluated elsewhere had normal hearing. In 8 others who were not tested (7 for practical 
reasons and 1 with Down syndrome and ENT follow-up elsewhere) HL was not suspected by 
members of the follow-up team or the parents. Information on HL was lacking in the 2 remaining 
children: One was suffering from mental retardation and autism and lacked cognitive ability for 
audiometry; one, seen at age 5 years before audiometry was introduced into our program, had died of 
multiple congenital anomalies before the next scheduled visit.  
Thus, 139 children underwent audiometry. We excluded the results of three 5-year-old participants 
because they could not be tested reliably (Figure 1). Therefore, the results of 136 children were 
analyzed; 104 of them (76%) were tested at age 5 years, 20 (15%) at 8 years, and 12 (9%) at 12 
years.  
Data on language development and intelligence at age 5 years had not been obtained in 28 children 
born before 1996 (because the follow-up program started in 2001) and in two 5-year-olds born after 
1996 (due to parental refusal). Thus, developmental evaluation at 5 years was performed in 106 
children (audiometry in 104 because in 2 of them audiometry was performed at 8 years); for 66 of 
these children developmental data at 2 years were also available. The Reynell receptive language 
development test and the Schlichting subtests for syntactical and lexical development were not 
administered to 17 children (practical reasons n=10; poor cognitive competence n=3; insufficient 
command of the Dutch language n=3; and language development tested elsewhere n=1). Of these 17 
children, 12 had normal hearing, 2 had moderate to severe unilateral HL (one sensorineural and one 
conductive), 1 had mild conductive unilateral HL and 2 had mild conductive bilateral HL. For 7 children 
tested at 5 years a reliable intelligence score could not be calculated (poor cognitive competence n=5; 
recent assessment elsewhere with intelligence within normal range n=1; assessment with non-verbal 
test due to hearing problems with intelligence in normal range n=1).  
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Table 1:  
Baseline and ECMO characteristics of participants 
 n = 136 
Boys/girls, n(%) 73/63 (54/46) 
Diagnosis, n(%) 
CDH 
MAS 
Other 
 
24 (18) 
73 (54) 
39 (29) 
Gestational age, wks, mean (SD) 39.6 (1.8) 
Birth weight, kg, mean (SD) 3.37 (0.57) 
Age at start ECMO, hrs, median (range) 25 (4-600) 
Oxygenation index prior to ECMO, median (range) 43 (13-130) 
Highest mean airway pressure, cm H2O, median (range) 20 (11-45) 
Time on ECMO, hrs, median (range) 133 (47-510) 
Duration of ventilation including ECMO, d, median (range) 12 (2-130) 
Oxygen requirement post extubation, n(%) 
1 day-1 wk 
1 wk- 1 mo 
> 1 mo 
Unknown 
 
54 (40) 
50 (37) 
18 (13) 
14 (10) 
Chronic lung disease, n(%) 
no 
yes 
unknown 
 
100 (74) 
27 (20) 
9 (7) 
CDH = congenital diaphragmatic hernia; MAS = meconium aspiration syndrome; remaining diagnoses 
consist of: persistent pulmonary hypertension n=18, sepsis n=8, pneumonia n=4, birth asphyxia n=2, 
cardiac disease n=2, other n=3. Chronic lung disease was defined as oxygen dependency at day 28. 
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The baseline characteristics of all participants are shown in Table 1. None of the baseline 
characteristics differed between children included in the analysis and those who were excluded or lost 
to follow-up (data not shown). The subgroup of 106 children who underwent developmental 
assessment at 5 years did not differ from the total study group (data not shown).  
 
Of the 136 children tested audiologically, 103 (75.7%) had normal hearing and 33 (24.3%) had a 
significant HL. Eleven children had SNHL only (8.1%); one child suffered from combined HL (0.7%); 
the remaining 21 children (15.4%) had conductive HL.  
Five children had bilateral SNHL (3.7% of the study population); in 2 of them (1.5%) SNHL was mild, 
symmetrical, and of high frequencies only. Three children (2.2%) had moderate to severe bilateral 
SNHL, symmetrical in 2 of them, with loss of both high and low frequencies. The characteristics of 
these 5 children are described in Table 2. All had normal cerebral ultrasound during ECMO treatment. 
Three needed special education; 2 of them for learning difficulties (Patient 1 with severe birth asphyxia 
and Patient 2 with mental retardation due to a partial chromosome X-duplication), and one for hearing 
problems (Patient 4). The other 2 children received regular education with extra support for hearing 
problems and attention deficit disorder (Patient 3) or language support (Patient 5, who was not a 
native Dutch speaker). 
 
SNHL in the remaining 7 children (5.1%) was unilateral; in 2 children it had resolved at follow-up. In 2 
of the other 5 it was mild, but 3 children (2.2% of the study population) had completely impaired 
hearing in one ear (ipsilateral cerebral infarction n=1; bacterial meningitis at age 1 month n=1; 
unknown cause n=1). All three had abnormal audiological examinations within the first months of life 
and HL had been diagnosed early. The patient with bacterial meningitis suffered from severe 
combined HL. 
 
Table 2: Characteristics of five children with bilateral sensorineural hearing loss. 
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CDH: congenital diaphragmatic hernia; MAS: meconium aspiration syndrome; PPHN: persistent pulmonary 
hypertension of the newborn; CLD: chronic lung disease; ADHD: attention deficit hyperactivity disorder; NA: not 
available, i.e. not performed; language development measured with the Reynell and Schlichting language tests; 
IQ: intelligence quotient measured with the RAKIT intelligence test,. * Assessment at 8 yrs (born before 1996): 
language development at 8 years measured with verbal subtests of the Wechsler Intelligence Scale.  
 
Hearing was normal in 19 of the 24 CDH patients (79.2%); only 2 of the 24 CDH patients (8.3%) had 
mild SNHL, which was unilateral in one of them. The other 3 CDH patients had conductive HL. The 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Hearing loss      
Description  
 
 
Right ear: 40 dB at 4 
kHz, 80 dB at 8 kHz; 
left ear: cup-shaped 
HL 45 dB at 2 kHz  
70 dB at 8 kHz 20 dB at 250 Hz; 
40-70 dB at 500 
Hz- 8 kHz 
30- 50 dB at 250 
Hz; 70- 100 dB at 
500 Hz- 8 kHz 
Max. 30 dB 
Neonatal screening NA; brainstem 
normal at 5 yrs 
NA Abnormal Normal ? 
Age diagnosis HL 8.0 yrs 8.0 yrs 0.2 yrs 1.1 yrs 5.3 yrs 
Risk factors      
Diagnosis Severe asphyxia CDH MAS, asphyxia PPHN MAS 
Comorbidity Pre-ECMO seizures  - - - - 
Medication Furosemide  
Phenobarbital  
Tobramycin (single 
dose) 
Phenobarbital Furosemide 
continuously 
Phenobarbital 
Erythromycin 
fluconazol 
Furosemide  
Phenobarbital  
Vancomycin 
Furosemide 
Age start ECMO 25 hours 20 hours 9 hours 284 hours 27 hours 
ECMO duration 96 hours 120 hours 184 hours 288 hours 137 hours 
Ventilation duration 12 days 37 days 22 days 36 days 9 days 
Outcome      
Hearing aids No No Yes Yes No 
Speech therapy At 8 yrs At 8 yrs At 2 (articulation) 
and 5 yrs 
At 5 yrs None 
Language 
development 
Below average* Below average* Average  Average Below average
Intelligence (IQ) 
 
 
62* 62* 85 99 74 
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proportions of children with normal hearing, SNHL or conductive HL did not differ between the three 
diagnosis categories (p=0.84, Chi-square test). 
 
At 2 years of age the median verbal and non-verbal developmental scores were in the normal range 
(Table 3). The verbal developmental scores differed between children with normal hearing, mild 
hearing loss, and moderate to severe hearing loss (p=0.028; Kruskal-Wallis H-test). Post-hoc testing 
revealed that the verbal developmental score for children with a normal hearing was significantly lower 
than that for children with mild hearing loss (p=0.007; Mann-Whitney test). The non-verbal scores did 
not differ between the three hearing groups (p=0.363; Kruskal-Wallis H-test). The results are shown in 
Table 3. 
 
At 5 years of age the median language and intelligence scores were in the normal range (Table 3). 
Receptive language development, syntactical language expression and lexical language expression 
did not differ between children with normal hearing, mild hearing loss, and moderate to severe hearing 
loss (p=0.800, p=0.639, p=0.876, respectively; Kruskal-Wallis H-test). The same was true for 
intelligence (p=0.886; Kruskal-Wallis H-test). 
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Table 3 Developmental results at 2 and 5 years following neonatal ECMO 
2 years 
Verbal score (n=66) 
     Mild hearing loss (n=13) 
     Moderate to severe hearing loss (n=5) 
     Normal hearing (n=48) 
 
Non-verbal score (n=66) 
     Mild hearing loss (n=13) 
     Moderate to severe hearing loss (n=5) 
     Normal hearing (n=48) 
 
5 years 
Reynell (n=89) 
     Mild hearing loss (n=18) 
     Moderate to severe hearing loss (n=4) 
     Normal hearing (n=67) 
 
Schlichting syntactical language expression (n=89) 
     Mild hearing loss (n=18) 
     Moderate to severe hearing loss (n=4) 
     Normal hearing (n=67) 
 
Schlichting lexical language expression (n=89) 
     Mild hearing loss (n= 18) 
     Moderate to severe hearing loss (n=4) 
     Normal hearing (n=67) 
 
Intelligence quotient (n=99) 
     Mild hearing loss (n=20) 
     Moderate to severe hearing loss (n=5) 
     Normal hearing (n=74) 
Median (range) 
98 (50-136) 
118 (51-134) 
96 (65-136) 
94 (50-134)* 
 
106 (48-133) 
112 (60-130) 
92 (64-133) 
103 (48-132) 
 
 
95 (56-138) 
99 (56-127) 
99 (85-108) 
95 (62-138) 
 
101 (50-141) 
107 (55-122) 
95 (84-115) 
101 (50-141) 
 
104 (55-133) 
112 (67-121) 
101 (96-119) 
102 (55-133) 
 
104 (68-132) 
115 (68-131) 
107 (90-132) 
103 (69-132) 
 
*significantly lower than scores in children with mild hearing loss (p=0.007; Mann-Whitney test) 
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Discussion 
In this study we found that 75.7% of children had normal hearing 5 to 12 years after neonatal VA-
ECMO treatment; 15.4% of children had conductive HL. SNHL was established in 12 of the 136 
children (8.8%). SNHL was bilateral in 5 (3.7%); three of them wore hearing aids and/or received 
special audiological care (2.2% of the total sample). Overall, the children's language development and 
intelligence at 2 and 5 years were normal. Language development and intelligence results of children 
with HL were not worse than those of children with normal hearing. 
  
Few epidemiologic data on hearing impairment in the normal pediatric population are available. In the 
United States it is estimated to occur in 1.1 per 1000 infants (25); a study in the Netherlands found that 
0.78 per 1000 infants had permanent hearing impairment (13). Recently, Cone and co-workers 
reported a 0.88% prevalence of SNHL in primary school-aged children (26). In 2009, Mehra and co-
workers concluded from audiometric screening studies that 3.1% of children and adolescents in the 
United States suffer from unilateral or bilateral hearing impairment (>20 dB). Those screening studies 
took place between 1958 and 1993 and most children were between 6 and 19 years old(25). We 
found an eightfold higher prevalence of HL (24.3%), mainly of conductive origin. A high prevalence of 
conductive HL within the first 24 months of life has been reported in very low birth weight infants, 
especially in those with chronic lung disease (up to 54.5%) (27). Nasally-placed tubes for ventilatory 
assistance and disturbed local immunity might be associated with chronic otitis media with effusion in 
infants up to two years of age(28). Although all of our patients had been ventilated neonatally, it is 
unclear whether nasal tube placement and discturbed immunity explain our results at the age of 5 
years, because our population was not born prematurely and the prevalence of conductive HL seems 
to decrease with age. Another possible explanation is that the 5-year-old children in our study may 
have suffered from recurrent respiratory tract infections with concomitant conductive HL. However, all 
these assumptions are speculative and do not seem to fully explain the discrepancy in findings. 
Further evaluation by ENT-surgeons will be needed to uncover the origin and clinical course of 
conductive HL in ECMO-treated patients. 
 
Regarding SNHL, Cheung and Robertson (6) reported a 7.5% overall prevalence of SNHL in ECMO 
survivors, ranging from 3 to 21% in six different ECMO centers in the United States. All reviewed 
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studies had been published before 1996. Fligor and co-workers found a 26% prevalence of bilateral 
SNHL in ECMO survivors born between 1986 and 1994 (7). Almost half of the children had delayed-
onset SNHL, and 72% had progressive HL. Cheung and co-workers also reported normal clinical 
neonatal screening results in children who developed SNHL. The prevalence of bilateral SNHL in our 
population is in accordance with data published on larger series in the United States (29, 30). One 
child with severe bilateral SNHL, who would have been eligible for the follow-up program, was 
evaluated elsewhere and her data had been excluded from our analysis. Should we have included her 
data, the prevalence of SNHL would have been 9.5% (13 of 137 cases) with bilateral HL in 4.4% (6 of 
137 children).  
In our study neonatal screening data were not available for 3 of 5 children with bilateral SNHL. One 
child failed to pass the neonatal screening and was referred for audiological care at an early stage. In 
one child who passed the neonatal screening test successfully, SNHL was diagnosed at 13 months, 
indicating delayed-onset SNHL.  
A high prevalence of SNHL has been reported in children with CDH, even those not treated with 
ECMO (7, 23, 24). Two of the 24 CDH patients in our study had mild SNHL (one patient with bilateral 
HL also had a partial chromosome X duplication). Similarly, Morando and co-workers (31) reported 
one patient with SNHL in a cohort of 26 CDH survivors not treated with ECMO. CDH is not the only 
risk factor for SNHL after ECMO treatment. Other reported factors are: treatment with 
aminoglycosides(7, 32),  furosemide, muscle relaxants (32), initiation of ECMO-treatment after >160 
hours (7), prolonged ECMO treatment, and pre-ECMO seizures(10)  A nationwide study in the 
Netherlands revealed that the only independent risk factors for HL in neonates receiving intensive care 
were severe birth asphyxia and assisted ventilation for ≥5 days (9). The small number of children with 
bilateral SNHL in the present study did not allow for multivariate analysis. Yet, all 5 patients with 
bilateral SNHL had between 2 and 5 of the above-mentioned risk factors. 
 
All our patients were treated with VA-ECMO. During this procedure deoxygenated blood is removed 
from the right internal jugular vein and oxygenated blood is returned through a cannula placed in the 
right carotid artery. Veno-venous (VV) ECMO is a technique that has now gained more acceptance – 
also in our institution - for use in patients with an isolated pulmonary disease without the need for 
cardiac support(33). Using this technique, the carotid artery need not be sacrificed and the normal 
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pulsatility to the systemic flow is maintained. The risk for central nervous system complications 
(bleeding, microthrombi or infarct) seems to be less in VV-ECMO than in VA-ECMO(33). The question 
is whether VV-ECMO could have reduced the prevalence of SNHL. Significant differences in mean 
cerebral blood flow velocities between VV- and VA-ECMO have been reported. with higher blood flow 
velocities in the basilar artery during VA-ECMO(34). This observation seems to contradict the 
hypothesis that VA-ECMO has a negative influence on cochlear perfusion. Taking into account that 
the etiology of SNHL in ECMO-treated patients is unclear and that many different factors may play a 
role, we assume that VV-ECMO likely would not have reduced HL prevalence. However, additional 
studies are needed to confirm this assumption. 
 
In the present study, results of language development and intelligence testing after neonatal ECMO 
treatment were favorable. Developmental test results of children with impaired hearing did not differ 
from those of children with normal hearing. Because children with unilateral HL may suffer from 
conductive hearing impairment in their best ear during upper airway infections, we related the 
developmental data to HL severity and not to HL laterality or origin. However, the small number of 
patients with HL does not allow for conclusions on the impact of early HL. Others have found that even 
mild bilateral HL compromises the development of language, communication skills and behavior at 
school age (35, 36). It seems, therefore, to be important to detect HL at an early stage and provide 
early intervention. 
 
For the main purpose of this study we described the characteristics of 5 children with purely bilateral 
SNHL (Table 2). Interestingly, two with profound SNHL diagnosed at an early age (at 0.2 years and 
1.1 years respectively; patients 3 and 4 in Table 2) and wearing hearing aids showed normal 
intelligence and language development. The other three children had been diagnosed later, and 
showed worse intelligence and language development. In all three, however, language development 
and/or intelligence might have been affected by comorbidity: Two had an underlying problem 
associated with impaired intelligence: severe birth asphyxia (patient 1; Table 2) and a partial 
duplication of chromosome X with mental retardation (patient 2; Table 2), respectively. The third was 
not a native Dutch speaker (patient 5; Table 2).  
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Conclusions 
In this cohort of survivors of neonatal ECMO the prevalence of SNHL was 8.8% which approximated 
that of larger series in the United States. Overall, these children demonstrated normal language 
development and intelligence, and children with HL did not perform worse.  In addition to the common 
practice of neonatal hearing screening and audiological follow-up of patients with severe birth 
asphyxia or (neonatal) meningitis, we suggest that adequate information for parents and caregivers 
and close follow-up of all children after neonatal ECMO treatment is important. Prompt referral to an 
ENT-department with expertise in profound audiological evaluation in children should be considered 
even at minor signals suspicious of hearing impairment. 
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List of abbreviations 
BOS 2-30: Bayley Developmental Scales 
BSID-II-NL: Bayley Scales of Infant Development – Second Edition – Dutch version 
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ECMO: extracorporeal membrane oxygenation 
HL: hearing loss 
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MAP: mean airway pressure 
MAS: meconium aspiration syndrome 
OI: oxygenation index 
PPHN: persistent pulmonary hypertension of the newborn 
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SNHL: sensorineural hearing loss 
VA: veno-arterial 
VV: veno-venous 
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Figure legends 
 
Figure 1: 
Flow chart. 
CDH = congenital diaphragmatic hernia 
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No follow-up, n=110: 
 76 died (46 CDH) 
 34 lost to follow up 
Unreliable test results n=3 
 
136 children with reliable audiometry 
measurements included 
262 children on ECMO between 
January 1992 and February 2005 
139 children tested 
152 children eligible 
No audiometry available, n=13 
 3 evaluated elsewhere 
 10 not tested 
22 
 
 
